Cardiovascular diseases and malignant neoplasms — what do they have in common?
https://doi.org/10.21886/2219-8075-2025-16-4-55-61
Abstract
Cardiovascular diseases, as malignant neoplasms, occupy a leading position in the structure of total mortality. One of the common side effects of the treatment of malignant neoplasms is cardiotoxicity, which subsequently complicates the pathogenetic therapy of the formation. The purpose of this review was to summarize and clarify existing ideas about the influence of various risk factors for cardiovascular diseases on the occurrence of cancer. The presented review allows us to study in detail the results of meta–analyses and large-scale studies that complement the understanding of classical behavioral factors such as smoking, alcohol consumption, poor nutrition and biological risk factors such as hypertension, obesity, diabetes mellitus, reflecting the contribution of these factors not only to the development of cardiovascular diseases, but also malignant neoplasms. The influence of these factors was analyzed from the perspective of pathogenetic mechanisms – oxidative stress and chronic inflammation, cardiotoxicity of the treatment. The review also focuses on contradictory data regarding the influence of any factor on the occurrence of these nosologies and summarizes the analyzed material.
Supporting agencies: This review article was prepared as part of the state assignment for the research topic “Immunological and Biochemical Predictors of Coronary Artery Calcification, Pathogenetic Justification of the Severity of Its Course, and Development of Tools for Predicting Cardiovascular Risk” (No. 1023022000034-7-3.1.3;3.2.4 dated 31 May 2024), approved by the Ministry of Health of the Russian Federation.
About the Authors
I. F. Shlyk
Rostov State Medical University
Russian Federation
Russian Federation
Irina F. Shlyk, Dr. Sci. (Med.), Associate Professor, Head of the Department of Outpatient and Emergency Therapy
Rostov-on-Don
V. D. Kechkina
Rostov State Medical University
Russian Federation
Russian Federation
Victoria D. Kechkina, 6th-year student of the Faculty of General Medicine
Rostov-on-Don
D. Yu. Besedina
Rostov State Medical University
Russian Federation
Russian Federation
Daria Yu. Besedina, Assistant, Department of Outpatient and Emergency Therapy
Rostov-on-Don
References
1. WHO. Global Cancer Burden Rising Amid Striking Inequities. 2024.
2. Rossiiskii statisticheskii ezhegodnik. Moscow; 2024. (In Russ.)
3. Wilcox NS, Amit U, Reibel JB, Berlin E, Howell K, et al. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024;21(9):617-631. https://doi.org/10.1038/s41569-024-01017-x.
4. Gao H, Chen Z, Yao Y, He Y, Hu X. Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer. Front Oncol. 2024;14:1453090. https://doi.org/10.3389/fonc.2024.1453090
5. Ewer MS, Yusuf SW, Asmis R, Abe JI. Editorial: Case reports in cardio-oncology: 2022. Front Cardiovasc Med. 2023;10:1235015. https://doi.org/10.3389/fcvm.2023.1235015
6. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889-3897. https://doi.org/10.1093/eurheartj/ehz766
7. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333-e465. Erratum in: Eur Heart J Cardiovasc Imaging. 2023;24(6):e98. https://doi.org/10.1093/ehjci/jeac106
8. Satpathy C, Kumar Mishra T, Singh S, Jha AK. Reverse cardio-oncology: A budding concept. Indian Heart J. 2023;75(6):398-402. https://doi.org/10.1016/j.ihj.2023.09.004
9. Raisi-Estabragh Z, Cooper J, McCracken C, Crosbie EJ, Walter FM, et al. Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer. Heart. 2023;109(13):1007-1015. https://doi.org/10.1136/heartjnl-2022-321888
10. Jiang C, Chen YX, Geng QS, Liu AB. Prevalence and clinical risk factors of cardiovascular disease in patients with cancer: a cross-sectional study. BMC Cardiovasc Disord. 2025;25(1):526. https://doi.org/10.1186/s12872-025-04976-2
11. Allison JD, Tanavin T, Yang Y, Birnbaum G, Khalid U. Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. Cardiovasc Toxicol. 2020;20(4):437-442. https://doi.org/10.1007/s12012-020-09562-w
12. Shiga T, Hiraide M. Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Curr Treat Options Oncol. 2020;21(4):27. https://doi.org/10.1007/s11864-020-0719-1
13. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17(8):503-522. https://doi.org/10.1038/s41569-020-0347-2
14. Banks E, Joshy G, Korda RJ, Stavreski B, Soga K, et al. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Med. 2019;17(1):128. https://doi.org/10.1186/s12916-019-1351-4
15. Pirro M, Ricciuti B, Rader DJ, Catapano AL, Sahebkar A, Banach M. High density lipoprotein cholesterol and cancer: Marker or causative? Prog Lipid Res. 2018;71:54-69. https://doi.org/10.1016/j.plipres.2018.06.001
16. Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management. JACC CardioOncol. 2019;1(2):238-251. https://doi.org/10.1016/j.jaccao.2019.11.009
17. Radišauskas R, Kuzmickienė I, Milinavičienė E, Everatt R. Hypertension, serum lipids and cancer risk: A review of epidemiological evidence. Medicina (Kaunas). 2016;52(2):89-98. https://doi.org/10.1016/j.medici.2016.03.002
18. Nam GE, Baek SJ, Choi HB, Han K, Kwak JM, et al. Association between Abdominal Obesity and Incident Colorectal Cancer: A Nationwide Cohort Study in Korea. Cancers (Basel). 2020;12(6):1368. https://doi.org/10.3390/cancers12061368
19. Kim CS, Han KD, Choi HS, Bae EH, Ma SK, Kim SW. Association of Hypertension and Blood Pressure With Kidney Cancer Risk: A Nationwide Population-Based Cohort Study. Hypertension. 2020;75(6):1439-1446. https://doi.org/10.1161/HYPERTENSIONAHA.120.14820
20. Xuan K, Zhao T, Sun C, Patel AS, Liu H, et al. The association between hypertension and colorectal cancer: a meta-analysis of observational studies. Eur J Cancer Prev. 2021;30(1):84-96. https://doi.org/10.1097/CEJ.0000000000000578
21. Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. https://doi.org/10.3389/fcvm.2023.1136340
22. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107. https://doi.org/10.1016/j.metabol.2018.10.011
23. Li B, Leung JCK, Chan LYY, Yiu WH, Tang SCW. A global perspective on the crosstalk between saturated fatty acids and Toll-like receptor 4 in the etiology of inflammation and insulin resistance. Prog Lipid Res. 2020;77:101020. https://doi.org/10.1016/j.plipres.2019.101020
24. Xu J, Lin H, Wu G, Zhu M, Li M. IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma. Front Oncol. 2021;11:760971. https://doi.org/10.3389/fonc.2021.760971
25. Yuan F, Wen W, Jia G, Long J, Shu XO, Zheng W. Serum Lipid Profiles and Cholesterol-Lowering Medication Use in Relation to Subsequent Risk of Colorectal Cancer in the UK Biobank Cohort. Cancer Epidemiol Biomarkers Prev. 2023;32(4):524-530. https://doi.org/10.1158/1055-9965.EPI-22-1170
26. Nouri M, Mohsenpour MA, Katsiki N, Ghobadi S, Jafari A, et al. Effect of Serum Lipid Profile on the Risk of Breast Cancer: Systematic Review and Meta-Analysis of 1,628,871 Women. J Clin Med. 2022;11(15):4503. https://doi.org/10.3390/jcm11154503
27. Quoc Lam B, Shrivastava SK, Shrivastava A, Shankar S, Srivastava RK. The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives. J Cell Mol Med. 2020;24(14):7706-7716. https://doi.org/10.1111/jcmm.15413
28. Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019;8(4):e011295. https://doi.org/10.1161/JAHA.118.011295
29. Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471(3):307-322. https://doi.org/10.1042/BJ20150497
30. Sona MF, Myung SK, Park K, Jargalsaikhan G. Type 1 diabetes mellitus and risk of cancer: a meta-analysis of observational studies. Jpn J Clin Oncol. 2018;48(5):426-433. https://doi.org/10.1093/jjco/hyy047
31. Carstensen B, Read SH, Friis S, Sund R, Keskimäki I, et al. Cancer incidence in persons with type 1 diabetes: a fivecountry study of 9,000 cancers in type 1 diabetic individuals. Diabetologia. 2016;59(5):980-988. https://doi.org/10.1007/s00125-016-3884-9
32. Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38(2):264-270. Erratum in: Diabetes Care. 2015;38(4):734-735. https://doi.org/10.2337/dc14-1996
33. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. https://doi.org/10.1136/bmj.g7607
34. Zhu B, Qu S. The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms. Front Endocrinol (Lausanne). 2022;13:800995. https://doi.org/10.3389/fendo.2022.800995
35. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer. 2011;128(3):635-643. https://doi.org/10.1002/ijc.25362
36. Jian Gang P, Mo L, Lu Y, Runqi L, Xing Z. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res. 2015;40(1):54-61. https://doi.org/10.3109/07435800.2014.934961
37. Long XJ, Lin S, Sun YN, Zheng ZF. Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(8):4097-4100. https://doi.org/10.7314/apjcp.2012.13.8.4097
38. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829- 841. Erratum in: N Engl J Med. 2011;364(13):1281. https://doi.org/10.1056/NEJMoa1008862
39. Izutkin D.A. Behavioral risk factors and the problem of cardio-vascular diseases. Medical Almanac. 2022;(3):21-28. (In Russ.) eLIBRARY ID: 49607239 EDN: FKSTRE
40. Phua ZJ, MacInnis RJ, Jayasekara H. Cigarette smoking and risk of second primary cancer: a systematic review and metaanalysis. Cancer Epidemiol. 2022;78:102160. https://doi.org/10.1016/j.canep.2022.102160
41. Yoo JE, Han K, Shin DW, Kim D, Kim BS, et al. Association Between Changes in Alcohol Consumption and Cancer Risk. JAMA Netw Open. 2022;5(8):e2228544. https://doi.org/10.1001/jamanetworkopen.2022.28544
42. Avraham S, Abu-Sharki S, Shofti R, Haas T, Korin B, et al. Early Cardiac Remodeling Promotes Tumor Growth and Metastasis. Circulation. 2020;142(7):670-683. https://doi.org/10.1161/CIRCULATIONAHA.120.046471
43. Kusiak A, Brady G. Bifurcation of signalling in human innate immune pathways to NF-kB and IRF family activation. Biochem Pharmacol. 2022;205:115246. https://doi.org/10.1016/j.bcp.2022.115246
44. Kusiak A, Brady G. Bifurcation of signalling in human innate immune pathways to NF-kB and IRF family activation. Biochem Pharmacol. 2022;205:115246. https://doi.org/10.1016/j.bcp.2022.115246
Review
For citations:
Shlyk I.F., Kechkina V.D., Besedina D.Yu. Cardiovascular diseases and malignant neoplasms — what do they have in common? Medical Herald of the South of Russia. 2025;16(4):55-61. (In Russ.) https://doi.org/10.21886/2219-8075-2025-16-4-55-61
Views:
29
Email this article 